Government Tightens Drug Quality Checks: Over 950 Actions Since 2022
India is stepping up its crackdown on substandard and unsafe medicines. According to the government, more than 1,100 cough syrup makers are now facing increased scrutiny, while over 950 regulatory actions have been initiated since 2022 against manufacturers over quality concerns.
The government has strengthened inspections, testing and enforcement across the pharmaceutical industry. More than 1,000 risk-based inspections have reportedly been carried out, leading to actions such as stop-production orders, licence suspensions and cancellations.
A major focus has been cough syrups, especially after concerns were raised over the quality of certain India-made products in overseas markets. Exported cough syrups now require testing at designated laboratories before they can be shipped.
For the Indian pharma industry, tighter regulation may create additional compliance costs in the short term, particularly for smaller manufacturers. But in the longer run, stronger quality standards can actually benefit established companies with robust manufacturing and compliance systems.
This is especially important because India is one of the world's largest suppliers of generic medicines. Maintaining confidence in "Made in India" pharmaceuticals is essential for protecting and expanding the country's global pharma business.
Learning Outcome: Regulation is not always negative for an industry. Tougher quality standards can hurt weaker players while strengthening organised companies that already maintain high manufacturing standards.